Initiatives to adjust the levels of FKBP51 or its interplay with HSP90 might hold therapeutic significance in treating Alzheimer’s disease, tauopathies, and disorders related to stress. Here, FKBP5 is linked to early-onset autosomal dominant Alzheimer disease.